Xvivo Perfusion AB (publ)
XVIPY · OTC
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Revenue | $178 | $219 | $228 | $198 |
| % Growth | -18.4% | -3.9% | 14.7% | – |
| Cost of Goods Sold | $46 | $58 | $52 | $51 |
| Gross Profit | $133 | $160 | $175 | $148 |
| % Margin | 74.4% | 73.4% | 77% | 74.5% |
| R&D Expenses | $32 | $35 | $56 | $31 |
| G&A Expenses | $18 | $23 | $23 | $28 |
| SG&A Expenses | $94 | $97 | $104 | $96 |
| Sales & Mktg Exp. | $76 | $74 | $81 | $67 |
| Other Operating Expenses | -$1 | $2 | $0 | $1 |
| Operating Expenses | $126 | $134 | $160 | $127 |
| Operating Income | $7 | $27 | $15 | $20 |
| % Margin | 4% | 12.2% | 6.8% | 10.3% |
| Other Income/Exp. Net | $0 | -$41 | $34 | $67 |
| Pre-Tax Income | -$3 | -$14 | $50 | $88 |
| Tax Expense | $5 | $2 | $13 | $2 |
| Net Income | $2 | -$12 | $36 | $86 |
| % Margin | 0.9% | -5.7% | 16% | 43.2% |
| EPS | 0.013 | -0.098 | 0.29 | 0.68 |
| % Growth | 112.8% | -133.6% | -57.4% | – |
| EPS Diluted | 0.013 | -0.098 | 0.29 | 0.68 |
| Weighted Avg Shares Out | 126 | 126 | 126 | 126 |
| Weighted Avg Shares Out Dil | 126 | 127 | 127 | 127 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $67 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $9 | $11 | $12 | $0 |
| EBITDA | $16 | $38 | $28 | $20 |
| % Margin | 9% | 17.3% | 12.3% | 10.3% |